Long-term progression-free survival in a case of hepatocellular carcinoma with vertebral metastasis treated with a reduced dose of sorafenib: Case report and review of the literature

Oncology Letters

Volumn 5, Issue 1, 2012, Pages 381-385

  Du, Juan ^a   Qian, Xiaoping ^a   Liu, Baorui ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Long term survival; Molecular targeted drug; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER THERAPY; CASE REPORT; CHEMOEMBOLIZATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LIFESTYLE MODIFICATION; LIVER CELL CARCINOMA; LONG TERM SURVIVAL; MALE; NEEDLE BIOPSY; OUTCOME ASSESSMENT; PERCUTANEOUS ETHANOL INJECTION; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; SPINE METASTASIS; TUMOR VOLUME;

EID: 84869021513     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.974     Document Type: Article

References (14)

1. Bosch FX, Ribes J, Cléries R, et al: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9: 191-211, 2005.
2. Llovet JM and Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48 Suppl 1: S20-37, 2008.
3. Gish RG, Porta C, Lazar L, et al: Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. JClin Oncol 25: 3069-3075, 2007.
4. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
5. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
6. Yoshida T, Hisamoto T, Akiba J, et al: Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 25: 6056-6066, 2006.
7. Huitzel-Melendez FD, Saltz LB, Song J, et al: Retrospective analysis of outcome in hepatocellular carcinoma (HCC) patients with hepatitis C (C+) versus B (B+) treated with sorafenib (abstract). Presented at the 2007 ASCO Gastrointestinal Cancers Symposium. (abstract 173), Orlando, FL, 2007.
8. Zhu AX: Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)? BMC Med 7: 42, 2009.
9. Strumberg D, Richly H, Hilger RA, et al: Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23: 965-972, 2005.
10. Petrelli A and Giordano S: From single-to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 15: 422-432, 2008.
11. Abbadessa G, Rimassa L, Pressiani T, et al: Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. World J Gastroenterol17: 2450-2453, 2011.
12. Edeline J, Boucher E, Rolland Y, et al: Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 118: 147-156, 2012.
13. Milano A, Perri F, Ciarmiello A, et al: Targeted-therapy and imaging response: a new paradigm for clinical evaluation? Rev Recent Clin Trials 6: 259-265, 2011.
14. Horger M, Lauer UM, Schraml C, et al: Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 9: 208-209, 2009.